TY - JOUR
T1 - Affective symptoms and family history of affective disorder in patients with tardive dyskinesia
AU - Schulze, T. G.
AU - Maroldt, A.
AU - Krauss, H.
AU - Knapp, M.
AU - Marwinski, K.
AU - Novo y Fernandez, A.
AU - Müller, D. J.
AU - Weber, T.
AU - Nöthen, M.
AU - Maier, W.
AU - Held, T.
AU - Rietschel, M.
PY - 1998/11/6
Y1 - 1998/11/6
N2 - Tardive dyskinesia (TD) represents a serious problem in patients receiving neuroleptic treatment. Besides the known risk factors, a genetically determined vulnerability seems probable. There are controversial findings on the influence of family history of affective disorder and individual history of affective symptomatology [Rush et al., 1982; Richardson et al., 1985; Wegner et al., 1985] on the development of TD. In our study, we examined 288 patients receiving long-term neuroleptic medication for the presence or ab-sence of TD according to RDC criteria. Patients with transient or developed TD and those with a DSM-IV diagnosis other than schizophrenia or schizoaffective disorder were excluded. Family history for affective disorder was assessed by family history method, interviewing the patient and whenever possible a first-degree relative. According to this interview, 27 patients had first-degree relatives with affective disorders. There was no correlation between a family history of affective disorder and the occurrence of TD. No different result was found when schizophrenic and schizoaffective patients were analyzed separately. In addition, we assessed patients for life-time history of affective symptoms by using SADS-LA interview and OPCRIT. While there was no correlation between depressive symptomatology and the occurrence of TD, we found significantly fewer patients with TD to display manic symptoms during life-time than patients never showing TD (P = 0.025). Therefore;, we hypothesize that life-time occurrence of manic symptoms might be considered a protective factor in the development of TD.
AB - Tardive dyskinesia (TD) represents a serious problem in patients receiving neuroleptic treatment. Besides the known risk factors, a genetically determined vulnerability seems probable. There are controversial findings on the influence of family history of affective disorder and individual history of affective symptomatology [Rush et al., 1982; Richardson et al., 1985; Wegner et al., 1985] on the development of TD. In our study, we examined 288 patients receiving long-term neuroleptic medication for the presence or ab-sence of TD according to RDC criteria. Patients with transient or developed TD and those with a DSM-IV diagnosis other than schizophrenia or schizoaffective disorder were excluded. Family history for affective disorder was assessed by family history method, interviewing the patient and whenever possible a first-degree relative. According to this interview, 27 patients had first-degree relatives with affective disorders. There was no correlation between a family history of affective disorder and the occurrence of TD. No different result was found when schizophrenic and schizoaffective patients were analyzed separately. In addition, we assessed patients for life-time history of affective symptoms by using SADS-LA interview and OPCRIT. While there was no correlation between depressive symptomatology and the occurrence of TD, we found significantly fewer patients with TD to display manic symptoms during life-time than patients never showing TD (P = 0.025). Therefore;, we hypothesize that life-time occurrence of manic symptoms might be considered a protective factor in the development of TD.
UR - http://www.scopus.com/inward/record.url?scp=33749083587&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33749083587&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:33749083587
SN - 1552-4841
VL - 81
SP - 526
EP - 527
JO - American Journal of Medical Genetics - Neuropsychiatric Genetics
JF - American Journal of Medical Genetics - Neuropsychiatric Genetics
IS - 6
ER -